Can a deprescribing team lighten the pill burden for kidney patients?
NCT ID NCT06324045
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study tests whether a team of doctors and pharmacists can safely reduce unnecessary medications in 424 adults with chronic kidney disease in Qatar. Participants will either receive the deprescribing intervention or usual care. The goal is to lower the number of risky or unneeded drugs and improve quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hamad Medical Corporation
RECRUITINGDoha, 3050, Qatar
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
deprescribing program (medication review and reduction by a multidisciplinary team)
What this could lead to
If successful, this could show that a structured deprescribing program safely reduces medication burden and improves quality of life for people with chronic kidney disease.
What could go wrong
This is a relatively small, single-country trial testing a behavioral intervention, so results may not apply broadly. The primary outcome focuses on reducing inappropriate medications, not on hard clinical endpoints like survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.